Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Rating Upgraded by Zacks Research

Amneal Pharmaceuticals (NASDAQ:AMRX) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Monday, Zacks reports.

A number of other equities research analysts also recently weighed in on the stock. Weiss Ratings upgraded shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. Barclays upped their price objective on shares of Amneal Pharmaceuticals from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Thursday, September 17th. Oppenheimer started coverage on shares of Amneal Pharmaceuticals in a research note on Wednesday, September 23rd. They issued an “outperform” rating and a $27.00 price objective for the company. UBS Group reissued a “buy” rating on shares of Amneal Pharmaceuticals in a research note on Thursday, October 1st. Finally, Wall Street Zen upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. Nine analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.25.

Amneal Pharmaceuticals Trading Up 2.0%

Shares of Amneal Pharmaceuticals stock opened at $21.44 on Monday. Amneal Pharmaceuticals has a 12-month low of $9.99 and a 12-month high of $21.46. The firm’s 50-day moving average price is $18.93 and its two-hundred day moving average price is $15.62.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.06. The business had revenue of $796.20 million during the quarter. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. Equities research analysts anticipate that Amneal Pharmaceuticals will post 0.95 EPS for the current year.

Insider Buying and Selling at Amneal Pharmaceuticals

In other news, EVP Jason B. Daly sold 210,000 shares of the business’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $17.40, for a total transaction of $3,654,000.00. Following the sale, the executive vice president directly owned 35,171 shares in the company, valued at approximately $611,975.40. The trade was a 85.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Nikita Shah sold 146,403 shares of the business’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total value of $2,563,516.53. Following the sale, the executive vice president owned 253,390 shares in the company, valued at approximately $4,436,858.90. This trade represents a 36.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 413,016 shares of company stock worth $7,216,567. 17.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Public Employees Retirement System of Ohio acquired a new stake in Amneal Pharmaceuticals during the 2nd quarter worth approximately $29,000. Fortitude Family Office LLC increased its position in Amneal Pharmaceuticals by 100.9% in the 3rd quarter. Fortitude Family Office LLC now owns 1,607 shares of the company’s stock valued at $32,000 after acquiring an additional 807 shares during the period. GAMMA Investing LLC increased its position in Amneal Pharmaceuticals by 54.9% in the 3rd quarter. GAMMA Investing LLC now owns 1,605 shares of the company’s stock valued at $32,000 after acquiring an additional 569 shares during the period. Sterling Capital Management LLC increased its position in Amneal Pharmaceuticals by 30.3% in the 3rd quarter. Sterling Capital Management LLC now owns 3,549 shares of the company’s stock valued at $71,000 after acquiring an additional 825 shares during the period. Finally, KBC Group NV bought a new position in shares of Amneal Pharmaceuticals during the first quarter valued at $80,000. Institutional investors own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include oral, injectable and inhaled medications, as well as complex dosage forms and other products designed to address areas where manufacturing or formulation requirements can be more challenging.

The company’s generics business offers medicines across a range of therapeutic categories, including central nervous system, cardiovascular, gastrointestinal, anti-infective and other treatments.